AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
A healthy hedge.(Fariba Ghodsian of Castle Creek LifeScience Partners)
Fariba Ghodsian
Castle Creek LifeScience Partners
Biotechnology's constant pace of innovation makes it an enthralling sector for investment opportunities. Pushing the boundaries of discovery provides the possibility for unprecedented gains and losses. When navigating this "final frontier," it helps to have a proven guide like Fariba Ghodsian.
Ghodsian, who currently heads up research for Castle Creek LifeScience Partners' $85 million biotech hedge fund, has had her fingers on the pulse of the industry for more than a decade. Ghodsian was a director of healthcare research at Roth Capital Partners, and a biotech analyst at Lehman Brothers, Sutro & Co./Tucker Anthony and Wedbush Morgan. She also worked in the industry and has a master's from MIT, an MBA from UCLA and a Phi) from Oxford.
During the past year, Ghodsian realized that her talents might be put to better use on the buy side. "There have been increasing problems on the sell side with the SEC and conflicts of interest brought up--and that makes things a lot more difficult going forward," say Ghodsian. She also took into account the difficult year biotech had weathered before she made the switch. "I thought that biotech stocks were at a level where they could be attractive for a buy-side fund," she says.
- Dr. Fariba Ghodsian Joins Trega Biosciences; Biotech Analyst Becomes Strategic...
- Press release article from: PR Newswire June 6, 1997 700+ words
SAN DIEGO, June 6 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA) (formerly Houghten Pharmaceuticals, Inc.) today announced that Fariba F. Ghodsian, Ph.D., has assumed the duties of strategic and financial advisor and acting chief financial officer. She replaces Terence E. McMorrow who has
- PARTNERSHIP RUMORED FOR ABGENIX, AMGEN.(Business)
- Newspaper article from: Daily News (Los Angeles, CA) July 4, 2003 700+ words
...I think it would make a lot of sense if Amgen acquired Abgenix,'' said Fariba Ghodsian, a portfolio manager at hedge fund Castle Creek Lifescience Partners in Beverly Hills. ``Amgen would probably like to have better access to Abgenix...
- Annual meeting feels like a version of 'Survivor': experts focus on getting...
- Magazine article from: San Diego Business Journal Webb, Marion March 3, 2003 700+ words
...traditional biotech financing model, Crooke said. And that is likely to add to the industry's financial woes, he added. Fariba Ghodsian, a biotech analyst with the venture capital group Castle Creek Partners LLC in Los Angeles, said some biotech casualties...
- Amgen Gets FDA Approval for New Anemia Drug.
- Newspaper article from: Knight Ridder/Tribune Business News July 23, 2002 700+ words
...The company has increased its Procrit sales force to 600 and amplified its direct-to-consumer advertising campaign. Fariba Ghodsian, an analyst with Roth Capital Partners in Los Angeles, said the companies have wiggle room to fight a price war because...
- AMGEN SEEKS TO HIKE ENBREL PRODUCTION.(Business)
- Newspaper article from: Daily News (Los Angeles, CA) August 24, 2002 700+ words
...ultimately hurt Amgen. Johnson & Johnson's Remicade has garnered strength amid Enbrel's paltry production levels. Fariba Ghodsian, analyst with Roth Capital Partners in Los Angeles, said many people have turned to Remicade because Enbrel wasn't available...
- Praecis Settles with Amgen over Development of Prostate Cancer Drug.
- Newspaper article from: Daily News (Los Angeles, California) (via Knight-Ridder/Tribune Business News) August 22, 2002 700+ words
...Guillord deals is Amgen's "way of cleaning house." "And I don't think Amgen's losing any sleep over this," said Fariba Ghodsian, analyst with Roth Capital Partners LLC in Los Angeles. "Disappointing FDA data led to Amgen's decision. They are...
- Amgen-Immunex Consolidation Efforts Get Under Way.
- Newspaper article from: Knight Ridder/Tribune Business News July 18, 2002 700+ words
...Sales of Enbrel, which is supplied by a German contractor, were $762 million in 2001. Roth Capital Partners analyst Fariba Ghodsian says Amgen will be under the gun to fix the Enbrel shortage quickly. A new manufacturing plant, the first of two expected...
- Rival's Arthritis Drug Beats Seattle-Area Firm for First Time.
- Newspaper article from: Knight Ridder/Tribune Business News April 23, 2002 700+ words
...conservative, and if a patient is responding well to a treatment, physicians are not inclined to change that," said Fariba Ghodsian, a health-care analyst with Roth Capital Partners. "Any delays could only worsen Immunex's situation and make it...